Back to News
Market Impact: 0.35

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

ZBHNNOX
Company FundamentalsAnalyst EstimatesAnalyst InsightsCorporate EarningsHealthcare & BiotechInvestor Sentiment & Positioning
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

Zimmer Biomet (ZBH), a musculoskeletal healthcare leader, is identified as a top value stock with a Zacks Rank #2 (Buy) and an 'A' Value Style Score, underpinned by a 12.66 forward P/E. The company's investment appeal is further bolstered by a 'B' VGM Score and recent positive analyst sentiment, with 11 analysts raising FY2025 earnings estimates, increasing the Zacks Consensus Estimate by $0.19 to $8.14 per share, and an average earnings surprise of +1.8%.

Analysis

Zimmer Biomet (ZBH) is presented as a compelling investment based on the Zacks quantitative rating system, which assigns it a #2 (Buy) rank. The company's primary appeal is for value-oriented investors, underscored by a top-tier 'A' Value Style Score and an attractive forward P/E ratio of 12.66. This valuation is supported by positive momentum in analyst sentiment, with 11 analysts having revised their fiscal 2025 earnings estimates upward within the last 60 days. This collective optimism has lifted the Zacks Consensus Estimate for fiscal 2025 by $0.19 to $8.14 per share. Furthermore, ZBH has demonstrated consistent operational performance, evidenced by an average positive earnings surprise of 1.8%. The combination of these factors—a favorable valuation, upward earnings revisions, and a history of exceeding expectations—positions the stock favorably within the framework described.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment